Beijing Airdoc Technology Co. Ltd. Class H (2251) AI Stock Analysis

• Market Cap: HK$1.17B
• Dividend Yield: N/A
• Average Volume (3M): 29.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: -32.17%
• EPS Growth: -1.20%
• Country: HK
• Employees: 248
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.02
• Shares Outstanding: 103,568,016
• 10 Day Avg. Volume: 29,230
• 30 Day Avg. Volume: 29,180
• PEG Ratio: -0.05
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 7.56
• P/FCF Ratio: -7.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -8.95
• Revenue Forecast (FY): HK$1.55B

• Rating: 40 Neutral
• Price Target: HK$12.50 ▼(-5.87% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues, persistent losses, and negative cash flows. Technical analysis indicates bearish momentum, with the stock trading below key moving averages. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, further weighing down the score.

Beijing Airdoc Technology Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Airdoc Technology Co. Ltd. Class H (2251) is a pioneering technology company focused on the development and application of artificial intelligence (AI) in the healthcare sector. The company specializes in AI-powered medical imaging and diagnostic solutions, aiming to enhance clinical decision-making and improve patient outcomes. Its core product offerings leverage advanced algorithms to provide accurate and efficient diagnostic services, particularly in the field of ophthalmology.

How the Company Makes Money

Beijing Airdoc Technology Co. Ltd. generates revenue primarily through the sale and licensing of its AI-driven diagnostic software to healthcare providers, hospitals, and clinics. The company also partakes in strategic partnerships with medical institutions and device manufacturers to integrate its technology into existing healthcare systems. Additionally, it may earn income from research collaborations and grants that support the development and refinement of its AI solutions. The effectiveness and reliability of its technology in improving diagnostic accuracy and efficiency are critical factors contributing to its financial performance.

Beijing Airdoc Technology Co. Ltd. Class H Financial Statement Overview

Summary

Beijing Airdoc Technology Co. Ltd. is facing significant financial challenges. The company struggles with declining revenues, persistent losses, and inefficiencies in operations. Despite a strong equity base, the lack of profitability and negative cash flows pose serious risks to financial stability. Strategic improvements are necessary to enhance revenue growth and operational efficiencies.

Income Statement

The company has experienced significant declines in revenue with a 23.35% decrease from 2023 to 2024. Gross profit margins remain relatively healthy at 55.42% in 2024, but net income is deeply negative, reflecting ongoing profitability challenges. The negative EBIT and EBITDA margins indicate operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 89.87% in 2024, indicating low financial leverage. However, the negative return on equity reflects losses and underutilization of equity capital. Total liabilities remain low, which reduces financial risk, but persistent negative net income impacts overall financial health.

Cash Flow

The company's cash flows are concerning, with zero operating and free cash flow in 2024. The inability to generate positive cash flow from operations raises sustainability concerns. Historical cash flows have been volatile, with significant negative free cash flow, highlighting challenges in managing cash effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	146.37M	156.37M	203.96M	113.66M	115.18M	47.67M
Gross Profit	97.02M	86.68M	125.13M	55.85M	70.24M	29.09M
EBITDA	-175.75M	-259.70M	-113.36M	-159.64M	-126.73M	-51.97M
Net Income	-176.63M	-255.46M	-132.53M	-180.00M	-142.63M	-80.06M
Balance Sheet
Total Assets	1.37B	1.41B	1.68B	1.74B	1.89B	435.75M
Cash, Cash Equivalents and Short-Term Investments	618.65M	774.82M	1.14B	1.41B	1.78B	374.70M
Total Debt	12.71M	31.88M	9.37M	8.01M	8.20M	519.00K
Total Liabilities	93.78M	134.86M	127.13M	68.59M	74.19M	27.30M
Stockholders Equity	1.27B	1.27B	1.54B	1.67B	1.82B	408.21M
Cash Flow
Free Cash Flow	-90.28M	-167.51M	8.02M	-392.55M	-140.11M	-64.77M
Operating Cash Flow	-97.04M	-165.43M	23.37M	-380.44M	-112.09M	-42.86M
Investing Cash Flow	234.62M	-11.34M	-385.14M	-154.43M	-22.01M	91.69M
Financing Cash Flow	-3.62M	-33.31M	-18.53M	-17.14M	1.55B	240.63M

Beijing Airdoc Technology Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2251, the sentiment is Negative. The current price of 13.28 is above the 20-day moving average (MA) of 12.88, below the 50-day MA of 13.89, and above the 200-day MA of 12.92, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 26.16 is Positive, neither overbought nor oversold. The STOCH value of 8.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2251.

Beijing Airdoc Technology Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2219	68 Neutral	HK$1.78B	9.34	7.31%	10.08%	-3.19%	-20.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3309	47 Neutral	HK$2.26B	―	-6.41%	1.11%	2.05%	-285.88%
2325	46 Neutral	HK$615.04M	-0.75	-47.91%	1.85%	-18.98%	-164.82%
3681	45 Neutral	HK$2.26B	―	-55.33%	―	-100.00%	30.68%
2158	41 Neutral	HK$5.08B	―	-2.97%	―	-12.31%	41.72%
2251	40 Neutral	HK$1.17B	-6.35	-12.97%	―	-32.17%	-1.20%

Beijing Airdoc Technology Co. Ltd. Class H Corporate Events

Beijing Airdoc Terminates Concert Party Agreement to Enhance Transparency

Beijing Airdoc Technology Co., Ltd. announced the termination of a concert party agreement among its major shareholders, Mr. Zhang, Mr. Gao, and Mr. Chen, effective October 17, 2025. This decision aims to optimize the company’s information disclosure system and prevent potential market misunderstandings. Despite the termination, the shareholders will continue to collaborate in the company’s best interests, offering a broader range of opinions that could benefit the company in the long term.

The most recent analyst rating on (HK:2251) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on Beijing Airdoc Technology Co. Ltd. Class H stock, see the HK:2251 Stock Forecast page.

Beijing Airdoc Technology Reports Improved Interim Financial Results

Beijing Airdoc Technology Co., Ltd. announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025, showing a revenue of RMB 83,713,000, a decrease from the previous year. Despite the revenue drop, the company reported a profit before tax of RMB 661,000, a significant improvement from the loss in the same period last year, indicating a positive shift in financial performance and potential stabilization in its market position.

The most recent analyst rating on (HK:2251) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Beijing Airdoc Technology Co. Ltd. Class H stock, see the HK:2251 Stock Forecast page.

Beijing Airdoc Technology Co., Ltd. Enhances Governance with New Nomination Committee

Beijing Airdoc Technology Co., Ltd. has established a Nomination Committee under its Board to enhance its governance structure. This committee is responsible for the selection and appointment of directors and senior management, aiming to rationalize board composition and improve corporate governance.

The most recent analyst rating on (HK:2251) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Beijing Airdoc Technology Co. Ltd. Class H stock, see the HK:2251 Stock Forecast page.

Beijing Airdoc Technology Projects Turnaround with AI-Driven Efficiency

Beijing Airdoc Technology Co., Ltd. announced an expected net profit of no more than RMB0.5 million for the first half of 2025, a significant improvement from a net loss of RMB81.5 million in the same period of 2024. This turnaround is attributed to the implementation of AI-driven solutions that improved operational efficiency and cost management, as well as strengthened financial management practices.

The most recent analyst rating on (HK:2251) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Beijing Airdoc Technology Co. Ltd. Class H stock, see the HK:2251 Stock Forecast page.

Beijing Airdoc Technology Schedules Board Meeting for Interim Results

Beijing Airdoc Technology Co., Ltd. has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for an interim dividend, which could impact shareholders and reflect the company’s financial health and strategic direction.

Beijing Airdoc Acquires Full Ownership of Subsidiary

Beijing Airdoc Technology Co., Ltd. has announced its acquisition of a 30% equity interest in a subsidiary, making it a wholly-owned entity. The acquisition, valued at RMB24.5 million, will allow the company to consolidate the subsidiary’s financial results into its own statements. The transaction is classified as a discloseable and connected transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but exempt from shareholder approval.

Beijing Airdoc Announces Board Resignation and Committee Restructuring

Beijing Airdoc Technology Co., Ltd. announced the resignation of Dr. HE Chao as an executive Director, effective July 29, 2025, to focus on personal commitments. The company also made changes to its board committees, appointing Dr. HUANG Yanlin as the chairman of the Nomination Committee and Ms. WANG Lin as a member, while Mr. QIN Yong joined the ESG Committee. These changes reflect the company’s ongoing adjustments to its governance structure.

Beijing Airdoc Technology Announces Board Composition and Roles

Beijing Airdoc Technology Co., Ltd. has announced the composition of its Board of Directors, detailing the roles and functions of each member. This announcement provides clarity on the leadership structure and committee memberships, which are crucial for the company’s governance and strategic direction.